The final decision was due to be published on the NICE website on 31 October and would have rejected ocrelizumab as an NHS treatment for primary progressive MS on the grounds of cost effectiveness.
The MS Trust now understands that this final decision has been postponed while further discussions take place between the drug company and NHS England. We welcome this move as it demonstrates a willingness on both sides to engage further in the debate around this drug which could have substantial impact on the lives of people with primary progressive MS.
No timeframes have yet been published, and the outcome is obviously unknown, but we will continue to campaign for equitable access to effective care options for everyone living with MS. Similarly we will continue to update you as and when further information becomes available following the NICE announcement.
Access to ocrelizumab for people living with PPMS would be a very welcome outcome to this further review, but we recognise that there are many factors which can influence the final decision. It is not yet clear how long, or what process will need to be followed, but it appears that access to a treatment which can slow down the progression of MS may have moved a step closer.
- David Martin, Chief Executive, MS Trust
MS in the Media
17 May 2019
- Statin has potential as SPMS drug
- EastEnders MS storyline
My Vespa adventure for the MS Trust
13 May 2019
For his next fundraising adventure, our supporter Nick Jolly will be riding 2,500 miles to Hungary on his Vespa scooter. He tells us about the inspiration behind his challenge.
"When you lose something, it makes you appreciate what you have"
13 May 2019
Danielle MacGillivray stars in our new film, Danielle. Here she tells us about her MS diagnosis, why she wanted to share her story in the film and learning to "appreciate the little things" every single day.